Pricing Log in Create free account

BioAge Labs, Inc. (BIOA) vs Emergent Biosolutions Inc. (EBS)

BioAge Labs, Inc. and Emergent Biosolutions Inc. are both Drug Manufacturers Specialty & Generic companies. Emergent Biosolutions Inc. is the larger, with a market value of $368.1M against $245.6M — 1.5× the size. Emergent Biosolutions Inc. has the higher net margin (−23.0% vs −912.3%) and the higher return on invested capital (−5.27% vs −118.3%). Across the 17 metrics below, Emergent Biosolutions Inc. leads on 9 and BioAge Labs, Inc. on 8.

Valuation

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 19.25
P/S 20.87 0.43 2.11
P/B 0.58 0.96 1.78
Price to free cash flow n/m 3.82 16.14
EV/EBITDA 0.95 20.89 12.58
EV/Sales (9.70) 1.00 2.73
Earnings yield (49.38%) (53.92%) (4.38%)
Free cash flow yield (112.36%) 26.15% 0.00%

Profitability

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Gross margin 100.00% 55.87% 53.94%
Operating margin (1,026.28%) (8.57%) 0.00%
Net margin (912.25%) (22.96%) 0.00%
Free cash flow margin (2,345.11%) 11.18% 0.00%
Return on equity (28.21%) (40.29%) (0.40%)
Return on assets (26.27%) (13.95%) (3.32%)
Return on invested capital (118.25%) (5.27%) 0.00%

Growth

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (9.56%) 10.01%
EPS growth (last fiscal year) 66.21% 125.83% 49.06%
Revenue growth, 5-year CAGR — (13.74%) 6.74%
Net income growth, 5-year CAGR — (29.64%) 0.00%

Health

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 1.70 0.05
Current ratio 17.19 5.42 2.31
Net debt to EBITDA 3.01 1.76 0.97

Dividend

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric BIOA EBS Drug Manufacturers Specialty & Generic median
Market cap 245.55m 368.14m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack